Mira Pharmaceuticals (MIRA) Common Equity (2022 - 2025)

Mira Pharmaceuticals (MIRA) has 4 years of Common Equity data on file, last reported at $10.4 million in Q4 2025.

• Quarterly Common Equity rose 372.34% year-over-year to $10.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.4 million (up 372.34% YoY) and the FY2025 annual result came in at $10.4 million, up 372.34% from the prior year.
• Common Equity improved to $10.4 million in Q4 2025 per MIRA's latest filing, from $7.5 million in the prior quarter.
• The five-year high for Common Equity was $10.4 million in Q4 2025, with the low at -$1.8 million in Q1 2023.
• Average Common Equity over 4 years is $3.0 million, with a median of $2.2 million recorded in 2024.
• Year-over-year, Common Equity soared 2432.48% in 2023 and sank 74.32% in 2025.
• Mira Pharmaceuticals' Common Equity stood at -$596232.0 in 2022, then soared by 833.67% to $4.4 million in 2023, then sank by 49.71% to $2.2 million in 2024, then soared by 372.34% to $10.4 million in 2025.
• Business Quant data shows MIRA's Common Equity at $10.4 million in Q4 2025, $7.5 million in Q3 2025, and $569859.0 in Q2 2025.